Rhumbline Advisers Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Rhumbline Advisers lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 419,727 shares of the medical research company’s stock after buying an additional 12,539 shares during the period. Rhumbline Advisers owned approximately 0.23% of IQVIA worth $82,480,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. PUREfi Wealth LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at $214,000. V Square Quantitative Management LLC boosted its position in shares of IQVIA by 2.6% during the fourth quarter. V Square Quantitative Management LLC now owns 4,370 shares of the medical research company’s stock valued at $859,000 after buying an additional 110 shares during the last quarter. SFE Investment Counsel boosted its position in shares of IQVIA by 4.1% during the fourth quarter. SFE Investment Counsel now owns 17,629 shares of the medical research company’s stock valued at $3,464,000 after buying an additional 690 shares during the last quarter. Great Lakes Retirement Inc. lifted its holdings in IQVIA by 6.2% in the fourth quarter. Great Lakes Retirement Inc. now owns 3,055 shares of the medical research company’s stock valued at $600,000 after acquiring an additional 179 shares during the period. Finally, Compound Global Advisors LLC bought a new position in IQVIA in the fourth quarter valued at about $334,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IQV. Stephens began coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $251.67.

IQVIA Stock Performance

NYSE IQV opened at $193.65 on Friday. The stock has a market capitalization of $35.15 billion, a PE ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The business has a 50 day simple moving average of $200.41 and a two-hundred day simple moving average of $218.21. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.